{
    "info": {
        "nct_id": "NCT05320198",
        "official_title": "A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia",
        "inclusion_criteria": "Inclusion Criteria for Participants with MF and Anemia\n\nParticipants are eligible for the study if all of the following criteria apply:\n\n1. Age 18 years or older at the time of signing the informed consent form (ICF).\n2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.63\n\n   For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.\n3. Washout of at least 28 days prior to Screening of the following treatments:\n\n   1. Androgens\n   2. Erythropoietin\n   3. Cladribine\n   4. Immunomodulators (lenalidomide, thalidomide)\n   5. Interferon alpha-2a\n   6. Luspatercept/sotatercept\n   7. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.\n\n   Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.\n4. Anemia:\n\n   For Phase 1b: Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.\n\n   For Phase 2:\n\n   TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening\n\n   TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening\n\n   nTD cohort: Non-transfusion dependence, baseline Hgb <10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion\n\n   Exploratory cohort: RBC TD or nTD with momelotinib or pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)\n5. Stable dosing of MF-directed therapy:\n\n   1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.\n   2. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD cohort and nTD cohort, JAK inhibitors allowed include ruxolitinib and fedratinib. For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review).\n   3. If the participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.\n6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.\n7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.\n8. Transferrin saturation <75% (local lab acceptable)\n9. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.\n10. Serum ferritin ≥30 50 µg/L at Screening.\n11. Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count <50,000/µL at Screening.\n12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.\n13. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening.\n14. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.\n15. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])\n    2. Intrauterine device in place for at least 3 months (female partner)\n    3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n16. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use highly effective contraception methods (listed below) on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:\n\n    1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    2. Intrauterine device in place for at least 3 months\n    3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).\n18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n19. Able to comply with all study procedures.\n\nInclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia\n\nParticipants are eligible for the MDS exploratory cohort if all of the following criteria apply:\n\n1. Age 18 years or older at the time of signing the ICF.\n2. Molecular International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate (ie, lower risk) MDS or MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.\n3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:\n\n   1. Androgens\n   2. Erythropoietin-stimulating agents\n   3. Luspatercept or sotatercept (ACE-011)\n   4. Imetelstat\n   5. Granulocyte colony-stimulating factor (GCSF) OR granulocyte-macrophage CSF (GM-CSF)\n   6. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.\n4. Anemia:\n\n   1. Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening\n   2. Medical history of ≤12 units of PRBC for MDS and anemia\n5. ECOG performance score ≤2\n6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening\n7. Transferrin saturation <75% (local lab acceptable)\n8. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review\n9. Serum ferritin ≥50 μg/L at Screening\n10. Platelet count ≥25,000/μL and <1,000,000/μL, and total WBC count <50,000/μL at Screening or otherwise approved by Sponsor\n11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula\n12. AST and ALT <3x ULN at Screening\n13. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.\n14. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])\n    2. Intrauterine device in place for at least 3 months (female partner)\n    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n15. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum FSH >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:\n\n    1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    2. Intrauterine device in place for at least 3 months\n    3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).\n17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n18. Able to comply with all study procedures.\n\nExclusion Criteria Exclusion Criteria for Participants with MF and Anemia\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical History, Participants with MF and Anemia\n\n1. Hereditary hemochromatosis\n2. Hemoglobinopathy or intrinsic RBC defect associated with anemia\n3. Total splenectomy\n4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression\n5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding\n6. Active immune-mediated hemolytic anemia\n7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening\n8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery\n9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:\n\n   1. Basal or squamous cell carcinoma\n   2. Carcinoma in situ of the cervix or the breast\n   3. Histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement\n10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening\n11. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug\n12. A history of anti-drug antibody formation\n13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%\n14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load\n15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Medical History, Participants with MF and Anemia\n16. Iron chelation therapy in the 28 days prior to Screening\n17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Medical History, Participants with MF and Anemia\n18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening\n19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Medical History, Participants with MF and Anemia\n20. Pregnant or lactating\n21. Condition or concomitant medication that would confound the ability to interpret study data\n22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study\n23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening\n\nExclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia\n\nParticipants are excluded from the MDS exploratory cohort if any of the following criteria apply:\n\nMedical History, Participants with MDS and Anemia\n\n1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases\n2. Peripheral blasts ≥5%\n3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy\n4. Prior treatment with >1anemia-directed therapies including:\n\n   * Luspatercept or sotatercept (ACE-011)\n   * Erythropoietin-stimulating agent\n   * Imetelstat\n5. Hereditary hemochromatosis\n6. Hemoglobinopathy or intrinsic RBC defect associated with anemia\n7. Total splenectomy\n8. Hematopoietic cell transplant within the past 10 years\n9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding\n10. Active immune-mediated hemolytic anemia\n11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening\n12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery\n13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:\n\n    1. basal or squamous cell carcinoma\n    2. carcinoma in situ of the cervix or the breast\n    3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement\n14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening\n15. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug\n16. A history of antidrug antibody formation\n17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%\n18. Active hepatitis B or C, or HIV with detectable viral load\n19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Participants with MDS and Anemia\n20. Iron chelation therapy in the 28 days prior to Screening\n21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Participants with MDS and Anemia\n22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Participants with MDS and Anemia\n23. Pregnant or lactating\n24. Condition or concomitant medication that would confound the ability to interpret study data\n25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study\n26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "5. ECOG performance score ≤2",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance score ≤2",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance score ≤2",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Washout of at least 28 days prior to Screening of the following treatments:",
                "criterions": [
                    {
                        "exact_snippets": "Washout of at least 28 days prior to Screening",
                        "criterion": "washout period",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Washout of at least 28 days prior to Screening",
                        "criterion": "washout period",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Washout of at least 28 days prior to Screening",
                        "criterion": "washout period",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Washout of at least 28 days prior to Screening",
                        "criterion": "washout period",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Carcinoma in situ of the cervix or the breast",
                "criterions": [
                    {
                        "exact_snippets": "Carcinoma in situ of the cervix",
                        "criterion": "carcinoma in situ of the cervix",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Carcinoma in situ of the ... breast",
                        "criterion": "carcinoma in situ of the breast",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Carcinoma in situ of the cervix",
                        "criterion": "carcinoma in situ of the cervix",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Carcinoma in situ of the ... breast",
                        "criterion": "carcinoma in situ of the breast",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding",
                "criterions": [
                    {
                        "exact_snippets": "Current anemia from iron deficiency",
                        "criterion": "anemia due to iron deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... vitamin B12 ... deficiency",
                        "criterion": "anemia due to vitamin B12 deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... folate deficiency",
                        "criterion": "anemia due to folate deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... infection",
                        "criterion": "anemia due to infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... bleeding",
                        "criterion": "anemia due to bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Current anemia from iron deficiency",
                        "criterion": "anemia due to iron deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... vitamin B12 ... deficiency",
                        "criterion": "anemia due to vitamin B12 deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... folate deficiency",
                        "criterion": "anemia due to folate deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... infection",
                        "criterion": "anemia due to infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... bleeding",
                        "criterion": "anemia due to bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Able to comply with all study procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Able to comply with all study procedures.",
                        "criterion": "compliance with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to comply with all study procedures.",
                        "criterion": "compliance with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Able to understand the study aims, procedures, and requirements",
                        "criterion": "understanding of study aims, procedures, and requirements",
                        "requirement": {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "provide written informed consent",
                        "criterion": "written informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to understand the study aims, procedures, and requirements",
                        "criterion": "understanding of study aims, procedures, and requirements",
                        "requirement": {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "provide written informed consent",
                        "criterion": "written informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Participants with MDS",
                        "criterion": "myelodysplastic syndromes (MDS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants with MDS",
                        "criterion": "myelodysplastic syndromes (MDS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Able to understand the study aims, procedures, and requirements",
                        "criterion": "understanding of study aims, procedures, and requirements",
                        "requirement": {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "provide written informed consent",
                        "criterion": "written informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to understand the study aims, procedures, and requirements",
                        "criterion": "understanding of study aims, procedures, and requirements",
                        "requirement": {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "provide written informed consent",
                        "criterion": "written informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Able to comply with all study procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Able to comply with all study procedures.",
                        "criterion": "compliance with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to comply with all study procedures.",
                        "criterion": "compliance with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Surgically sterile hysterectomy",
                        "criterion": "hysterectomy",
                        "requirement": {
                            "requirement_type": "surgical sterility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bilateral oophorectomy",
                        "criterion": "bilateral oophorectomy",
                        "requirement": {
                            "requirement_type": "surgical sterility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bilateral tubal ligation",
                        "criterion": "bilateral tubal ligation",
                        "requirement": {
                            "requirement_type": "surgical sterility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Surgically sterile hysterectomy",
                                "criterion": "hysterectomy",
                                "requirement": {
                                    "requirement_type": "surgical sterility",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                                "criterion": "barrier method contraception",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "bilateral oophorectomy",
                                "criterion": "bilateral oophorectomy",
                                "requirement": {
                                    "requirement_type": "surgical sterility",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                                "criterion": "barrier method contraception",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "bilateral tubal ligation",
                                "criterion": "bilateral tubal ligation",
                                "requirement": {
                                    "requirement_type": "surgical sterility",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                                "criterion": "barrier method contraception",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening",
                "criterions": [
                    {
                        "exact_snippets": "Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening",
                        "criterion": "infusion of hematopoietic stem cell transplant",
                        "requirement": {
                            "requirement_type": "anticipated timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "months after Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening",
                        "criterion": "infusion of hematopoietic stem cell transplant",
                        "requirement": {
                            "requirement_type": "anticipated timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "months after Screening"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Participants are excluded from the study if any of the following criteria apply:",
                "criterions": [
                    {
                        "exact_snippets": "Participants are excluded from the study if any of the following criteria apply:",
                        "criterion": "exclusion criteria statement",
                        "requirement": {
                            "requirement_type": "statement",
                            "expected_value": "This is an introductory statement indicating that specific exclusion criteria will follow; no atomic patient property is tested in this line."
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants are excluded from the study if any of the following criteria apply:",
                        "criterion": "exclusion criteria statement",
                        "requirement": {
                            "requirement_type": "statement",
                            "expected_value": "This is an introductory statement indicating that specific exclusion criteria will follow; no atomic patient property is tested in this line."
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. If the participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.",
                "criterions": [
                    {
                        "exact_snippets": "participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required",
                        "criterion": "prior use of JAK inhibitor or hydroxyurea",
                        "requirement": {
                            "requirement_type": "discontinuation prior to screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required",
                        "criterion": "prior use of JAK inhibitor or hydroxyurea",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required",
                        "criterion": "prior use of JAK inhibitor or hydroxyurea",
                        "requirement": {
                            "requirement_type": "discontinuation prior to screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required",
                        "criterion": "prior use of JAK inhibitor or hydroxyurea",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%",
                "criterions": [
                    {
                        "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "inadequately controlled"
                        }
                    },
                    {
                        "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "NYHA classification",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "known to have left ventricular ejection fraction <35%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "inadequately controlled"
                                }
                            },
                            {
                                "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "NYHA classification",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "known to have left ventricular ejection fraction <35%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Intrauterine device in place for at least 3 months",
                "criterions": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Anemia:",
                "criterions": [
                    {
                        "exact_snippets": "Anemia:",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Anemia:",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Luspatercept/sotatercept",
                "criterions": [
                    {
                        "exact_snippets": "Luspatercept/sotatercept",
                        "criterion": "Luspatercept or sotatercept use",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": "Luspatercept or sotatercept"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Luspatercept/sotatercept",
                        "criterion": "Luspatercept or sotatercept use",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": "Luspatercept or sotatercept"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria for Participants with MF and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "MF",
                        "criterion": "myelofibrosis (MF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "MF",
                        "criterion": "myelofibrosis (MF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Active immune-mediated hemolytic anemia",
                "criterions": [
                    {
                        "exact_snippets": "Active immune-mediated hemolytic anemia",
                        "criterion": "immune-mediated hemolytic anemia",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active immune-mediated hemolytic anemia",
                        "criterion": "immune-mediated hemolytic anemia",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Cladribine",
                "criterions": [
                    {
                        "exact_snippets": "Cladribine",
                        "criterion": "cladribine",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cladribine",
                        "criterion": "cladribine",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. AST and ALT <3x ULN at Screening",
                "criterions": [
                    {
                        "exact_snippets": "AST ... <3x ULN at Screening",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT <3x ULN at Screening",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "AST ... <3x ULN at Screening",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT <3x ULN at Screening",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Medical History, Participants with MF and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Participants with MF",
                        "criterion": "myelofibrosis (MF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with ... Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants with MF",
                        "criterion": "myelofibrosis (MF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with ... Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Hemoglobinopathy or intrinsic RBC defect associated with anemia",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobinopathy",
                        "criterion": "hemoglobinopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "intrinsic RBC defect associated with anemia",
                        "criterion": "intrinsic RBC defect associated with anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Hemoglobinopathy",
                        "criterion": "hemoglobinopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "intrinsic RBC defect associated with anemia",
                        "criterion": "intrinsic RBC defect associated with anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "timing relative to screening",
                            "expected_value": "prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "incomplete recovery from any previous surgery",
                        "criterion": "recovery from previous surgery",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "time since surgery",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "timing relative to screening",
                                    "expected_value": "prior to Screening"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "incomplete recovery from any previous surgery",
                        "criterion": "recovery from previous surgery",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.",
                        "criterion": "hematopoietic stem cell transplant infusion",
                        "requirement": {
                            "requirement_type": "anticipated_timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "months after Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.",
                        "criterion": "hematopoietic stem cell transplant infusion",
                        "requirement": {
                            "requirement_type": "anticipated_timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "months after Screening"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).",
                "criterions": [
                    {
                        "exact_snippets": "Negative urine pregnancy test (females of childbearing potential)",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "females of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "females of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at Screening (Days 28 to 2)",
                        "criterion": "timing of test",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "females of childbearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "females of childbearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "childbearing potential",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Negative urine pregnancy test (females of childbearing potential)",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "at Screening (Days 28 to 2)",
                        "criterion": "timing of test",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Androgens",
                "criterions": [
                    {
                        "exact_snippets": "Androgens",
                        "criterion": "androgens",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Androgens",
                        "criterion": "androgens",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Intrauterine device in place for at least 3 months",
                "criterions": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression",
                "criterions": [
                    {
                        "exact_snippets": "Hematopoietic cell transplant within the past 2 years",
                        "criterion": "hematopoietic cell transplant",
                        "requirement": {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "graft vs host disease requiring immunosuppression",
                        "criterion": "graft vs host disease",
                        "requirement": {
                            "requirement_type": "immunosuppression requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Hematopoietic cell transplant within the past 2 years",
                        "criterion": "hematopoietic cell transplant",
                        "requirement": {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "graft vs host disease requiring immunosuppression",
                        "criterion": "graft vs host disease",
                        "requirement": {
                            "requirement_type": "immunosuppression requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug",
                "criterions": [
                    {
                        "exact_snippets": "Known allergic reaction to any study drug excipient",
                        "criterion": "allergic reaction to study drug excipient",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anaphylaxis to any food or drug",
                        "criterion": "anaphylaxis to food or drug",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known allergic reaction to any study drug excipient",
                        "criterion": "allergic reaction to study drug excipient",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anaphylaxis to any food or drug",
                        "criterion": "anaphylaxis to food or drug",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Hereditary hemochromatosis",
                "criterions": [
                    {
                        "exact_snippets": "Hereditary hemochromatosis",
                        "criterion": "hereditary hemochromatosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hereditary hemochromatosis",
                        "criterion": "hereditary hemochromatosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                "criterions": [
                    {
                        "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                        "criterion": "liver iron concentration by MRI",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "mg/g dry weight"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                        "criterion": "liver iron concentration by MRI",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 months of eligibility confirmation by central review"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                        "criterion": "liver iron concentration by MRI",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "mg/g dry weight"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                        "criterion": "liver iron concentration by MRI",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 months of eligibility confirmation by central review"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Age 18 years or older at the time of signing the informed consent form (ICF).",
                "criterions": [
                    {
                        "exact_snippets": "Age 18 years or older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age 18 years or older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score ≤2",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score ≤2",
                        "criterion": "ECOG performance score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Active immune-mediated hemolytic anemia",
                "criterions": [
                    {
                        "exact_snippets": "Active immune-mediated hemolytic anemia",
                        "criterion": "immune-mediated hemolytic anemia",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active immune-mediated hemolytic anemia",
                        "criterion": "immune-mediated hemolytic anemia",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Luspatercept or sotatercept (ACE-011)",
                "criterions": [
                    {
                        "exact_snippets": "Luspatercept or sotatercept (ACE-011)",
                        "criterion": "luspatercept or sotatercept (ACE-011) administration",
                        "requirement": {
                            "requirement_type": "administration",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Luspatercept or sotatercept (ACE-011)",
                        "criterion": "luspatercept or sotatercept (ACE-011) administration",
                        "requirement": {
                            "requirement_type": "administration",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:",
                "criterions": [
                    {
                        "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                        "criterion": "sexual partner's childbearing potential",
                        "requirement": {
                            "requirement_type": "partner_gender",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                        "criterion": "sexual partner's childbearing potential",
                        "requirement": {
                            "requirement_type": "partner_childbearing_potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "agreement_to_use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                                "criterion": "sexual partner's childbearing potential",
                                "requirement": {
                                    "requirement_type": "partner_gender",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                                "criterion": "sexual partner's childbearing potential",
                                "requirement": {
                                    "requirement_type": "partner_childbearing_potential",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "agreement_to_use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 8,
                                                "unit": "weeks"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Intrauterine device in place for at least 3 months (female partner)",
                "criterions": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "(female partner)",
                        "criterion": "female partner",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "(female partner)",
                        "criterion": "female partner",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.",
                "criterions": [
                    {
                        "exact_snippets": "the washout period must be completed prior to collection of Screening blood samples",
                        "criterion": "washout period",
                        "requirement": {
                            "requirement_type": "completion timing",
                            "expected_value": "must be completed prior to collection of Screening blood samples"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "the washout period must be completed prior to collection of Screening blood samples",
                        "criterion": "washout period",
                        "requirement": {
                            "requirement_type": "completion timing",
                            "expected_value": "must be completed prior to collection of Screening blood samples"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.",
                "criterions": [
                    {
                        "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "Screening"
                        }
                    },
                    {
                        "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": ">=2x ULN"
                        }
                    },
                    {
                        "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "attribution",
                            "expected_value": "ineffective erythropoiesis (as determined by Investigator)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "timepoint",
                                "expected_value": "Screening"
                            }
                        },
                        {
                            "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<",
                                    "value": 2,
                                    "unit": "ULN"
                                }
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": ">=2x ULN"
                            }
                        },
                        {
                            "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "attribution",
                                "expected_value": "ineffective erythropoiesis (as determined by Investigator)"
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Confirmed successful vasectomy",
                        "criterion": "vasectomy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "confirmed successful"
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Confirmed successful vasectomy",
                        "criterion": "vasectomy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "confirmed successful"
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use highly effective contraception methods (listed below) on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:",
                "criterions": [
                    {
                        "exact_snippets": "If female",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    },
                    {
                        "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration of amenorrhea",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening",
                        "criterion": "serum follicle-stimulating hormone (FSH) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy)",
                        "criterion": "time since surgical menopause",
                        "requirement": {
                            "requirement_type": "duration since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "agreeable to use highly effective contraception methods ... on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agreeable to use highly effective contraception methods ... on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "If female",
                    "criterion": "sex",
                    "requirement": {
                        "requirement_type": "value",
                        "expected_value": "female"
                    }
                },
                "then_criteria": {
                    "or_criteria": [
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                                    "criterion": "menopausal status",
                                    "requirement": {
                                        "requirement_type": "status",
                                        "expected_value": "postmenopausal"
                                    }
                                },
                                {
                                    "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                                    "criterion": "menopausal status",
                                    "requirement": {
                                        "requirement_type": "duration of amenorrhea",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 12,
                                            "unit": "months"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening",
                                    "criterion": "serum follicle-stimulating hormone (FSH) level",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": ">",
                                            "value": 40,
                                            "unit": "mIU/mL"
                                        }
                                    }
                                }
                            ]
                        },
                        {
                            "exact_snippets": "at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy)",
                            "criterion": "time since surgical menopause",
                            "requirement": {
                                "requirement_type": "duration since surgery",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 6,
                                    "unit": "weeks"
                                }
                            }
                        },
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "agreeable to use highly effective contraception methods ... on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                                    "criterion": "contraception use",
                                    "requirement": {
                                        "requirement_type": "agreement to use contraception",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "agreeable to use highly effective contraception methods ... on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                                    "criterion": "contraception use",
                                    "requirement": {
                                        "requirement_type": "duration of contraception use",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 8,
                                            "unit": "weeks"
                                        }
                                    }
                                }
                            ]
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "7. Total splenectomy",
                "criterions": [
                    {
                        "exact_snippets": "Total splenectomy",
                        "criterion": "splenectomy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "total"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total splenectomy",
                        "criterion": "splenectomy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "total"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding",
                "criterions": [
                    {
                        "exact_snippets": "Current anemia from iron deficiency",
                        "criterion": "anemia due to iron deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... vitamin B12 ... deficiency",
                        "criterion": "anemia due to vitamin B12 deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... folate deficiency",
                        "criterion": "anemia due to folate deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... infection",
                        "criterion": "anemia due to infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... bleeding",
                        "criterion": "anemia due to bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Current anemia from iron deficiency",
                        "criterion": "anemia due to iron deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... vitamin B12 ... deficiency",
                        "criterion": "anemia due to vitamin B12 deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... folate deficiency",
                        "criterion": "anemia due to folate deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... infection",
                        "criterion": "anemia due to infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current anemia from ... bleeding",
                        "criterion": "anemia due to bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Luspatercept or sotatercept (ACE-011)",
                "criterions": [
                    {
                        "exact_snippets": "Luspatercept or sotatercept (ACE-011)",
                        "criterion": "prior treatment with luspatercept or sotatercept (ACE-011)",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Luspatercept or sotatercept (ACE-011)",
                        "criterion": "prior treatment with luspatercept or sotatercept (ACE-011)",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. A history of antidrug antibody formation",
                "criterions": [
                    {
                        "exact_snippets": "A history of antidrug antibody formation",
                        "criterion": "antidrug antibody formation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A history of antidrug antibody formation",
                        "criterion": "antidrug antibody formation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Anemia:",
                "criterions": [
                    {
                        "exact_snippets": "Anemia:",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Anemia:",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "MDS",
                        "criterion": "myelodysplastic syndromes (MDS)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "MDS",
                        "criterion": "myelodysplastic syndromes (MDS)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Interferon alpha-2a",
                "criterions": [
                    {
                        "exact_snippets": "Interferon alpha-2a",
                        "criterion": "Interferon alpha-2a",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": "Interferon alpha-2a"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Interferon alpha-2a",
                        "criterion": "Interferon alpha-2a",
                        "requirement": {
                            "requirement_type": "exposure or use",
                            "expected_value": "Interferon alpha-2a"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Participants are excluded from the MDS exploratory cohort if any of the following criteria apply:",
                "criterions": [
                    {
                        "exact_snippets": "Participants are excluded from the MDS exploratory cohort",
                        "criterion": "MDS exploratory cohort participation",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants are excluded from the MDS exploratory cohort",
                        "criterion": "MDS exploratory cohort participation",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug",
                "criterions": [
                    {
                        "exact_snippets": "Known allergic reaction to any study drug excipient",
                        "criterion": "allergic reaction to study drug excipient",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anaphylaxis to any food or drug",
                        "criterion": "anaphylaxis to food or drug",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known allergic reaction to any study drug excipient",
                        "criterion": "allergic reaction to study drug excipient",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anaphylaxis to any food or drug",
                        "criterion": "anaphylaxis to food or drug",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Stroke ... within 3 months prior to Screening",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "deep vein thrombosis ... within 3 months prior to Screening",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 3 months prior to Screening",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 3 months prior to Screening",
                        "criterion": "arterial embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Stroke ... within 3 months prior to Screening",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "deep vein thrombosis ... within 3 months prior to Screening",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 3 months prior to Screening",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 3 months prior to Screening",
                        "criterion": "arterial embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. Pregnant or lactating",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Iron chelation therapy in the 28 days prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Iron chelation therapy in the 28 days prior to Screening",
                        "criterion": "iron chelation therapy",
                        "requirement": {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Iron chelation therapy in the 28 days prior to Screening",
                        "criterion": "iron chelation therapy",
                        "requirement": {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with hypomethylating agent",
                        "criterion": "prior treatment with hypomethylating agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... other acute myeloid leukemia (AML)-like combination chemotherapy",
                        "criterion": "prior treatment with AML-like combination chemotherapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior treatment with hypomethylating agent",
                        "criterion": "prior treatment with hypomethylating agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... other acute myeloid leukemia (AML)-like combination chemotherapy",
                        "criterion": "prior treatment with AML-like combination chemotherapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. carcinoma in situ of the cervix or the breast",
                "criterions": [
                    {
                        "exact_snippets": "carcinoma in situ of the cervix",
                        "criterion": "carcinoma in situ of the cervix",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "carcinoma in situ of the ... breast",
                        "criterion": "carcinoma in situ of the breast",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "carcinoma in situ of the cervix",
                        "criterion": "carcinoma in situ of the cervix",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "carcinoma in situ of the ... breast",
                        "criterion": "carcinoma in situ of the breast",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "21. Condition or concomitant medication that would confound the ability to interpret study data",
                "criterions": [
                    {
                        "exact_snippets": "Condition ... that would confound the ability to interpret study data",
                        "criterion": "condition",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "concomitant medication that would confound the ability to interpret study data",
                        "criterion": "concomitant medication",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Condition ... that would confound the ability to interpret study data",
                        "criterion": "condition",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "concomitant medication that would confound the ability to interpret study data",
                        "criterion": "concomitant medication",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Transferrin saturation <75% (local lab acceptable)",
                "criterions": [
                    {
                        "exact_snippets": "Transferrin saturation <75% (local lab acceptable)",
                        "criterion": "transferrin saturation",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Transferrin saturation <75% (local lab acceptable)",
                        "criterion": "transferrin saturation",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria Exclusion Criteria for Participants with MF and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Participants with MF and Anemia",
                        "criterion": "myelofibrosis (MF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with MF and Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants with MF and Anemia",
                        "criterion": "myelofibrosis (MF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with MF and Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion dependence",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "PRBC units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "PRBC units"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion dependence",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "over the 84 days immediately prior to Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion dependence",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "PRBC units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "PRBC units"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion dependence",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "over the 84 days immediately prior to Screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Hematopoietic cell transplant within the past 10 years",
                "criterions": [
                    {
                        "exact_snippets": "Hematopoietic cell transplant within the past 10 years",
                        "criterion": "hematopoietic cell transplant",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hematopoietic cell transplant within the past 10 years",
                        "criterion": "hematopoietic cell transplant",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Hemoglobinopathy or intrinsic RBC defect associated with anemia",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobinopathy",
                        "criterion": "hemoglobinopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "intrinsic RBC defect associated with anemia",
                        "criterion": "intrinsic RBC defect associated with anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Hemoglobinopathy",
                        "criterion": "hemoglobinopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "intrinsic RBC defect associated with anemia",
                        "criterion": "intrinsic RBC defect associated with anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Medical history of ≤12 units of PRBC for MDS and anemia",
                "criterions": [
                    {
                        "exact_snippets": "Medical history of ≤12 units of PRBC for MDS and anemia",
                        "criterion": "PRBC transfusion history",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "units"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Medical history of ≤12 units of PRBC for MDS and anemia",
                        "criterion": "PRBC transfusion history",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "units"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Medical History, Participants with MDS and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Participants with MDS",
                        "criterion": "myelodysplastic syndrome (MDS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with ... Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants with MDS",
                        "criterion": "myelodysplastic syndrome (MDS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with ... Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Confirmed successful vasectomy",
                        "criterion": "vasectomy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "confirmed successful"
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Confirmed successful vasectomy",
                        "criterion": "vasectomy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "confirmed successful"
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Erythropoietin-stimulating agent",
                "criterions": [
                    {
                        "exact_snippets": "Erythropoietin-stimulating agent",
                        "criterion": "erythropoietin-stimulating agent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Erythropoietin-stimulating agent",
                        "criterion": "erythropoietin-stimulating agent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%",
                "criterions": [
                    {
                        "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "inadequately controlled"
                        }
                    },
                    {
                        "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "NYHA classification",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "known to have left ventricular ejection fraction <35%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "inadequately controlled"
                                }
                            },
                            {
                                "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "NYHA classification",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "known to have left ventricular ejection fraction <35%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:",
                "criterions": [
                    {
                        "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                        "criterion": "sexual partner's childbearing potential",
                        "requirement": {
                            "requirement_type": "partner sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                        "criterion": "sexual partner's childbearing potential",
                        "requirement": {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                            "criterion": "sexual partner's childbearing potential",
                            "requirement": {
                                "requirement_type": "partner sex",
                                "expected_value": "female"
                            }
                        },
                        {
                            "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                            "criterion": "sexual partner's childbearing potential",
                            "requirement": {
                                "requirement_type": "partner childbearing potential",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "agreement to use contraception",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                            "criterion": "contraception use",
                            "requirement": {
                                "requirement_type": "duration of contraception use",
                                "expected_value": {
                                    "comparisons": [
                                        {
                                            "operator": ">=",
                                            "value": 8,
                                            "unit": "weeks"
                                        }
                                    ]
                                }
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "8. Transferrin saturation <75% (local lab acceptable)",
                "criterions": [
                    {
                        "exact_snippets": "Transferrin saturation <75% (local lab acceptable)",
                        "criterion": "transferrin saturation",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Transferrin saturation <75% (local lab acceptable)",
                        "criterion": "transferrin saturation",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion requirement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "PRBC units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "PRBC units"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion requirement",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "over the 84 days immediately prior to Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion requirement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "PRBC units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "PRBC units"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion requirement",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "over the 84 days immediately prior to Screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.",
                "criterions": [
                    {
                        "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                        "criterion": "liver iron concentration by MRI",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "mg/g dry weight"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                        "criterion": "liver iron concentration by MRI",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 3 months of eligibility confirmation by central review"
                        }
                    },
                    {
                        "exact_snippets": "Required for TD high participants only",
                        "criterion": "participant transfusion dependence status",
                        "requirement": {
                            "requirement_type": "group membership",
                            "expected_value": "TD high participants only"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Required for TD high participants only",
                    "criterion": "participant transfusion dependence status",
                    "requirement": {
                        "requirement_type": "group membership",
                        "expected_value": "TD high participants only"
                    }
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                            "criterion": "liver iron concentration by MRI",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<",
                                    "value": 7,
                                    "unit": "mg/g dry weight"
                                }
                            }
                        },
                        {
                            "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                            "criterion": "liver iron concentration by MRI",
                            "requirement": {
                                "requirement_type": "timing",
                                "expected_value": "within 3 months of eligibility confirmation by central review"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "20. Iron chelation therapy in the 28 days prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Iron chelation therapy in the 28 days prior to Screening",
                        "criterion": "iron chelation therapy",
                        "requirement": {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Iron chelation therapy in the 28 days prior to Screening",
                        "criterion": "iron chelation therapy",
                        "requirement": {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. A history of anti-drug antibody formation",
                "criterions": [
                    {
                        "exact_snippets": "A history of anti-drug antibody formation",
                        "criterion": "anti-drug antibody formation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A history of anti-drug antibody formation",
                        "criterion": "anti-drug antibody formation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Participants with MDS and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Change in anticoagulant therapy regimen within 8 weeks prior to Screening",
                        "criterion": "anticoagulant therapy regimen",
                        "requirement": {
                            "requirement_type": "change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants with MDS and Anemia",
                        "criterion": "myelodysplastic syndrome (MDS) and anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Change in anticoagulant therapy regimen within 8 weeks prior to Screening",
                        "criterion": "anticoagulant therapy regimen",
                        "requirement": {
                            "requirement_type": "change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to Screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Participants with MDS and Anemia",
                        "criterion": "myelodysplastic syndrome (MDS) and anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Imetelstat",
                "criterions": [
                    {
                        "exact_snippets": "Imetelstat",
                        "criterion": "Imetelstat",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Imetelstat",
                        "criterion": "Imetelstat",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Stable dosing of MF-directed therapy:",
                "criterions": [
                    {
                        "exact_snippets": "Stable dosing of MF-directed therapy",
                        "criterion": "MF-directed therapy dosing",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Stable dosing of MF-directed therapy",
                        "criterion": "MF-directed therapy dosing",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Medical History, Participants with MF and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Change in anticoagulant therapy regimen within 8 weeks prior to Screening",
                        "criterion": "anticoagulant therapy regimen",
                        "requirement": {
                            "requirement_type": "change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Change in anticoagulant therapy regimen within 8 weeks prior to Screening",
                        "criterion": "anticoagulant therapy regimen",
                        "requirement": {
                            "requirement_type": "change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to Screening"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Total splenectomy",
                "criterions": [
                    {
                        "exact_snippets": "Total splenectomy",
                        "criterion": "total splenectomy",
                        "requirement": {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total splenectomy",
                        "criterion": "total splenectomy",
                        "requirement": {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "23. Pregnant or lactating",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Participation in any other clinical protocol or investigational study",
                        "criterion": "participation in other clinical protocol or investigational study",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "that involves administration of experimental therapy and/or therapeutic devices",
                        "criterion": "administration of experimental therapy or therapeutic devices",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to Screening",
                        "criterion": "time since participation in other clinical protocol or investigational study",
                        "requirement": {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participation in any other clinical protocol or investigational study",
                                "criterion": "participation in other clinical protocol or investigational study",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "that involves administration of experimental therapy and/or therapeutic devices",
                                "criterion": "administration of experimental therapy or therapeutic devices",
                                "requirement": {
                                    "requirement_type": "exposure",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "within 30 days prior to Screening",
                        "criterion": "time since participation in other clinical protocol or investigational study",
                        "requirement": {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Androgens",
                "criterions": [
                    {
                        "exact_snippets": "Androgens",
                        "criterion": "androgens",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Androgens",
                        "criterion": "androgens",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Stroke ... within 6 months prior to Screening",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "deep vein thrombosis ... within 6 months prior to Screening",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 6 months prior to Screening",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 6 months prior to Screening",
                        "criterion": "arterial embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Stroke ... within 6 months prior to Screening",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "deep vein thrombosis ... within 6 months prior to Screening",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 6 months prior to Screening",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "pulmonary or arterial embolism within 6 months prior to Screening",
                        "criterion": "arterial embolism",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Erythropoietin-stimulating agents",
                "criterions": [
                    {
                        "exact_snippets": "Erythropoietin-stimulating agents",
                        "criterion": "erythropoietin-stimulating agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Erythropoietin-stimulating agents",
                        "criterion": "erythropoietin-stimulating agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Hereditary hemochromatosis",
                "criterions": [
                    {
                        "exact_snippets": "Hereditary hemochromatosis",
                        "criterion": "hereditary hemochromatosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hereditary hemochromatosis",
                        "criterion": "hereditary hemochromatosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).",
                "criterions": [
                    {
                        "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at Screening (Days 28 to 2)"
                        }
                    },
                    {
                        "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "females of childbearing potential"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                                "criterion": "urine pregnancy test",
                                "requirement": {
                                    "requirement_type": "result",
                                    "expected_value": "negative"
                                }
                            },
                            {
                                "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                                "criterion": "urine pregnancy test",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "at Screening (Days 28 to 2)"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                        "criterion": "urine pregnancy test",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "females of childbearing potential"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Participation in any other clinical protocol or investigational study",
                        "criterion": "participation in other clinical protocol or investigational study",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "that involves administration of experimental therapy and/or therapeutic devices",
                        "criterion": "administration of experimental therapy and/or therapeutic devices",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to Screening",
                        "criterion": "time since participation in other clinical protocol or investigational study",
                        "requirement": {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participation in any other clinical protocol or investigational study",
                                "criterion": "participation in other clinical protocol or investigational study",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "that involves administration of experimental therapy and/or therapeutic devices",
                                "criterion": "administration of experimental therapy and/or therapeutic devices",
                                "requirement": {
                                    "requirement_type": "exposure",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "within 30 days prior to Screening",
                        "criterion": "time since participation in other clinical protocol or investigational study",
                        "requirement": {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "incomplete recovery from any previous surgery",
                        "criterion": "recovery from previous surgery",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": "incomplete"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "time since surgery",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "prior to Screening"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "incomplete recovery from any previous surgery",
                        "criterion": "recovery from previous surgery",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": "incomplete"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Participants with MDS and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Positive direct antiglobulin test",
                        "criterion": "direct antiglobulin test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "reactive RBC eluate at Screening",
                        "criterion": "RBC eluate",
                        "requirement": {
                            "requirement_type": "reactivity at Screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with MDS and Anemia",
                        "criterion": "myelodysplastic syndrome (MDS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with MDS and Anemia",
                        "criterion": "anemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants with MDS and Anemia",
                                "criterion": "myelodysplastic syndrome (MDS)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Participants with MDS and Anemia",
                                "criterion": "anemia",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Positive direct antiglobulin test",
                        "criterion": "direct antiglobulin test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "reactive RBC eluate at Screening",
                        "criterion": "RBC eluate",
                        "requirement": {
                            "requirement_type": "reactivity at Screening",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "24. Condition or concomitant medication that would confound the ability to interpret study data",
                "criterions": [
                    {
                        "exact_snippets": "Condition ... that would confound the ability to interpret study data",
                        "criterion": "condition",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "concomitant medication that would confound the ability to interpret study data",
                        "criterion": "concomitant medication",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Condition ... that would confound the ability to interpret study data",
                        "criterion": "condition",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "concomitant medication that would confound the ability to interpret study data",
                        "criterion": "concomitant medication",
                        "requirement": {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Intrauterine device in place for at least 3 months (female partner)",
                "criterions": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "(female partner)",
                        "criterion": "female partner",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intrauterine device in place",
                        "criterion": "intrauterine device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months",
                        "criterion": "intrauterine device duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "(female partner)",
                        "criterion": "female partner",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) <3x upper limit of normal (ULN) at Screening",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) <3x upper limit of normal (ULN) at Screening",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Erythropoietin",
                "criterions": [
                    {
                        "exact_snippets": "Erythropoietin",
                        "criterion": "erythropoietin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Erythropoietin",
                        "criterion": "erythropoietin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                "criterions": [
                    {
                        "exact_snippets": "Other medical or psychiatric condition ... that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                        "criterion": "other medical or psychiatric condition",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    },
                    {
                        "exact_snippets": "laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                        "criterion": "laboratory finding (not specifically noted above)",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Other medical or psychiatric condition ... that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                        "criterion": "other medical or psychiatric condition",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    },
                    {
                        "exact_snippets": "laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                        "criterion": "laboratory finding (not specifically noted above)",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Prior treatment with >1anemia-directed therapies including:",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with >1 anemia-directed therapies",
                        "criterion": "prior anemia-directed therapies",
                        "requirement": {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment with >1 anemia-directed therapies",
                        "criterion": "prior anemia-directed therapies",
                        "requirement": {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                "criterions": [
                    {
                        "exact_snippets": "Other medical or psychiatric condition ... that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                        "criterion": "other medical or psychiatric condition",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    },
                    {
                        "exact_snippets": "laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                        "criterion": "other laboratory finding",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "not_criteria": {
                                "exact_snippets": "Other medical or psychiatric condition ... that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                                "criterion": "other medical or psychiatric condition",
                                "requirement": {
                                    "requirement_type": "risk assessment",
                                    "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "not_criteria": {
                                "exact_snippets": "laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                                "criterion": "other laboratory finding",
                                "requirement": {
                                    "requirement_type": "risk assessment",
                                    "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Imetelstat",
                "criterions": [
                    {
                        "exact_snippets": "Imetelstat",
                        "criterion": "Imetelstat",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Imetelstat",
                        "criterion": "Imetelstat",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Participants are eligible for the study if all of the following criteria apply:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "1. Age 18 years or older at the time of signing the ICF.",
                "criterions": [
                    {
                        "exact_snippets": "Age 18 years or older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age 18 years or older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Medical History, Participants with MF and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Positive direct antiglobulin test",
                        "criterion": "direct antiglobulin test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "reactive RBC eluate at Screening",
                        "criterion": "RBC eluate",
                        "requirement": {
                            "requirement_type": "reactivity at Screening",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Positive direct antiglobulin test",
                        "criterion": "direct antiglobulin test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "reactive RBC eluate at Screening",
                        "criterion": "RBC eluate",
                        "requirement": {
                            "requirement_type": "reactivity at Screening",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:",
                "criterions": [
                    {
                        "exact_snippets": "Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts.",
                        "criterion": "malignancy (excluding MDS or MDS/MPN without excess blasts)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts.",
                        "criterion": "malignancy (excluding MDS or MDS/MPN without excess blasts)",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts.",
                        "criterion": "malignancy (excluding MDS or MDS/MPN without excess blasts)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts.",
                        "criterion": "malignancy (excluding MDS or MDS/MPN without excess blasts)",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "For Phase 2:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Hydroxyurea",
                        "criterion": "hydroxyurea treatment",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if taking any other treatment for MF, stable for at least 28 days prior to Screening",
                        "criterion": "other treatment for MF",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if taking any other treatment for MF, stable for at least 28 days prior to Screening",
                        "criterion": "other treatment for MF",
                        "requirement": {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Hydroxyurea",
                        "criterion": "hydroxyurea treatment",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "if taking any other treatment for MF, stable for at least 28 days prior to Screening",
                                "criterion": "other treatment for MF",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "if taking any other treatment for MF, stable for at least 28 days prior to Screening",
                                "criterion": "other treatment for MF",
                                "requirement": {
                                    "requirement_type": "stability duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:",
                "criterions": [
                    {
                        "exact_snippets": "Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies",
                        "criterion": "washout period for prior anemia/neutropenia-directed therapies",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies",
                        "criterion": "washout period for prior anemia/neutropenia-directed therapies",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load",
                "criterions": [
                    {
                        "exact_snippets": "Hepatitis B ... with detectable viral load",
                        "criterion": "Hepatitis B infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis B ... with detectable viral load",
                        "criterion": "Hepatitis B infection",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis C ... with detectable viral load",
                        "criterion": "Hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hepatitis C ... with detectable viral load",
                        "criterion": "Hepatitis C infection",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "human immunodeficiency virus (HIV) with detectable viral load",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "human immunodeficiency virus (HIV) with detectable viral load",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Hepatitis B ... with detectable viral load",
                                "criterion": "Hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Hepatitis B ... with detectable viral load",
                                "criterion": "Hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "viral load detectability",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Hepatitis C ... with detectable viral load",
                                "criterion": "Hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Hepatitis C ... with detectable viral load",
                                "criterion": "Hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "viral load detectability",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "human immunodeficiency virus (HIV) with detectable viral load",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "human immunodeficiency virus (HIV) with detectable viral load",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "viral load detectability",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Active hepatitis B or C, or HIV with detectable viral load",
                "criterions": [
                    {
                        "exact_snippets": "Active hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "HIV with detectable viral load",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "HIV with detectable viral load",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active hepatitis B",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active hepatitis C",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "HIV with detectable viral load",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "HIV with detectable viral load",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "viral load detectability",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Participants are eligible for the MDS exploratory cohort if all of the following criteria apply:",
                "criterions": [
                    {
                        "exact_snippets": "Participants are eligible for the MDS exploratory cohort",
                        "criterion": "eligibility for MDS exploratory cohort",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants are eligible for the MDS exploratory cohort",
                        "criterion": "eligibility for MDS exploratory cohort",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula",
                "criterions": [
                    {
                        "exact_snippets": "eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula",
                        "criterion": "eGFR (estimated glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    },
                    {
                        "exact_snippets": "eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula",
                        "criterion": "eGFR (estimated glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "CKD-EPI formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "eGFR \u001930 mL/min/1.73 m2 by the CKD-EPI formula",
                        "criterion": "eGFR (estimated glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    },
                    {
                        "exact_snippets": "eGFR \u001930 mL/min/1.73 m2 by the CKD-EPI formula",
                        "criterion": "eGFR (estimated glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "CKD-EPI formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (≥3 months)",
                        "criterion": "hormonal contraceptive use",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier contraceptive method use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (\u00193 months)",
                        "criterion": "hormonal contraceptive use",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier contraceptive method use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
                        "criterion": "hemoglobin (Hgb) level",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
                        "criterion": "hemoglobin (Hgb) level",
                        "requirement": {
                            "requirement_type": "number of assessments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "assessments"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
                        "criterion": "hemoglobin (Hgb) level",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": "84 days prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
                        "criterion": "hemoglobin (Hgb) level",
                        "requirement": {
                            "requirement_type": "RBC transfusion",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
                        "criterion": "hemoglobin (Hgb) level and RBC transfusion",
                        "requirement": {
                            "requirement_type": "Hgb value",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
                        "criterion": "hemoglobin (Hgb) level and RBC transfusion",
                        "requirement": {
                            "requirement_type": "RBC transfusion",
                            "expected_value": "periodically during the 84 days prior to Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Baseline Hgb of <10 g/dL on \u00193 assessments over 84 days prior to Screening, without RBC transfusion",
                                "criterion": "hemoglobin (Hgb) level",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 10,
                                        "unit": "g/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Baseline Hgb of <10 g/dL on \u00193 assessments over 84 days prior to Screening, without RBC transfusion",
                                "criterion": "hemoglobin (Hgb) level",
                                "requirement": {
                                    "requirement_type": "number of assessments",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "assessments"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Baseline Hgb of <10 g/dL on \u00193 assessments over 84 days prior to Screening, without RBC transfusion",
                                "criterion": "hemoglobin (Hgb) level",
                                "requirement": {
                                    "requirement_type": "time period",
                                    "expected_value": "84 days prior to Screening"
                                }
                            },
                            {
                                "exact_snippets": "Baseline Hgb of <10 g/dL on \u00193 assessments over 84 days prior to Screening, without RBC transfusion",
                                "criterion": "hemoglobin (Hgb) level",
                                "requirement": {
                                    "requirement_type": "RBC transfusion",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
                                "criterion": "hemoglobin (Hgb) level and RBC transfusion",
                                "requirement": {
                                    "requirement_type": "Hgb value",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 10,
                                        "unit": "g/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
                                "criterion": "hemoglobin (Hgb) level and RBC transfusion",
                                "requirement": {
                                    "requirement_type": "RBC transfusion",
                                    "expected_value": "periodically during the 84 days prior to Screening"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Serum ferritin ≥50 μg/L at Screening",
                "criterions": [
                    {
                        "exact_snippets": "Serum ferritin ≥50 μg/L at Screening",
                        "criterion": "serum ferritin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "μg/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum ferritin \u001e50 \u00181g/L at Screening",
                        "criterion": "serum ferritin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "\u00181g/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "For Phase 1b: Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "number of assessments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "assessments"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "84 days prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "without RBC transfusion",
                        "criterion": "RBC transfusion",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                        "criterion": "hemoglobin level and RBC transfusion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                        "criterion": "hemoglobin level and RBC transfusion",
                        "requirement": {
                            "requirement_type": "RBC transfusion periodicity",
                            "expected_value": "periodically"
                        }
                    },
                    {
                        "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                        "criterion": "hemoglobin level and RBC transfusion",
                        "requirement": {
                            "requirement_type": "TD participant status",
                            "expected_value": "not meeting criteria for TD participant"
                        }
                    },
                    {
                        "exact_snippets": "The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening",
                        "criterion": "baseline hemoglobin value",
                        "requirement": {
                            "requirement_type": "lowest value",
                            "expected_value": "during the 84 days prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion dependence",
                        "requirement": {
                            "requirement_type": "RBC transfusion frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "units PRBC"
                            }
                        }
                    },
                    {
                        "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening",
                        "criterion": "RBC transfusion dependence",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "84 days immediately prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period",
                        "criterion": "RBC transfusion interval",
                        "requirement": {
                            "requirement_type": "maximum interval without transfusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period",
                        "criterion": "RBC transfusion interval",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "84 day period"
                        }
                    },
                    {
                        "exact_snippets": "the last transfusion must be within 28 days prior to Screening",
                        "criterion": "timing of last RBC transfusion",
                        "requirement": {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Hgb <10 g/dL on \u00193 assessments over 84 days prior to Screening",
                                        "criterion": "hemoglobin level",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<",
                                                "value": 10,
                                                "unit": "g/dL"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Hgb <10 g/dL on \u00193 assessments over 84 days prior to Screening",
                                        "criterion": "hemoglobin level",
                                        "requirement": {
                                            "requirement_type": "number of assessments",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 3,
                                                "unit": "assessments"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Hgb <10 g/dL on \u00193 assessments over 84 days prior to Screening",
                                        "criterion": "hemoglobin level",
                                        "requirement": {
                                            "requirement_type": "time window",
                                            "expected_value": "84 days prior to Screening"
                                        }
                                    },
                                    {
                                        "exact_snippets": "without RBC transfusion",
                                        "criterion": "RBC transfusion",
                                        "requirement": {
                                            "requirement_type": "absence",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                                                "criterion": "hemoglobin level and RBC transfusion",
                                                "requirement": {
                                                    "requirement_type": "quantity",
                                                    "expected_value": {
                                                        "operator": "<",
                                                        "value": 10,
                                                        "unit": "g/dL"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                                                "criterion": "hemoglobin level and RBC transfusion",
                                                "requirement": {
                                                    "requirement_type": "RBC transfusion periodicity",
                                                    "expected_value": "periodically"
                                                }
                                            },
                                            {
                                                "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                                                "criterion": "hemoglobin level and RBC transfusion",
                                                "requirement": {
                                                    "requirement_type": "TD participant status",
                                                    "expected_value": "not meeting criteria for TD participant"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening",
                                        "criterion": "baseline hemoglobin value",
                                        "requirement": {
                                            "requirement_type": "lowest value",
                                            "expected_value": "during the 84 days prior to Screening"
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening",
                                                "criterion": "RBC transfusion dependence",
                                                "requirement": {
                                                    "requirement_type": "RBC transfusion frequency",
                                                    "expected_value": {
                                                        "operator": ">=",
                                                        "value": 6,
                                                        "unit": "units PRBC"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening",
                                                "criterion": "RBC transfusion dependence",
                                                "requirement": {
                                                    "requirement_type": "time window",
                                                    "expected_value": "84 days immediately prior to Screening"
                                                }
                                            },
                                            {
                                                "exact_snippets": "There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period",
                                                "criterion": "RBC transfusion interval",
                                                "requirement": {
                                                    "requirement_type": "maximum interval without transfusion",
                                                    "expected_value": {
                                                        "operator": "<=",
                                                        "value": 42,
                                                        "unit": "days"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period",
                                                "criterion": "RBC transfusion interval",
                                                "requirement": {
                                                    "requirement_type": "time window",
                                                    "expected_value": "84 day period"
                                                }
                                            },
                                            {
                                                "exact_snippets": "the last transfusion must be within 28 days prior to Screening",
                                                "criterion": "timing of last RBC transfusion",
                                                "requirement": {
                                                    "requirement_type": "time since last transfusion",
                                                    "expected_value": {
                                                        "operator": "<=",
                                                        "value": 28,
                                                        "unit": "days prior to Screening"
                                                    }
                                                }
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (≥3 months)",
                        "criterion": "hormonal contraceptive use",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier contraceptive method use",
                        "requirement": {
                            "requirement_type": "concurrent_use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (\u00193 months)",
                        "criterion": "hormonal contraceptive use",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier contraceptive method use",
                        "requirement": {
                            "requirement_type": "concurrent_use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Tubal ligation",
                        "criterion": "tubal ligation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "single male partner with vasectomy",
                        "criterion": "male partner vasectomy",
                        "requirement": {
                            "requirement_type": "partner vasectomy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "method type",
                            "expected_value": [
                                "condom (male)",
                                "condom (female)",
                                "diaphragm"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Tubal ligation",
                        "criterion": "tubal ligation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "single male partner with vasectomy",
                        "criterion": "male partner vasectomy",
                        "requirement": {
                            "requirement_type": "partner vasectomy status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "method type",
                            "expected_value": [
                                "condom (male)",
                                "condom (female)",
                                "diaphragm"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Immunomodulators (lenalidomide, thalidomide)",
                "criterions": [
                    {
                        "exact_snippets": "Immunomodulators (lenalidomide, thalidomide)",
                        "criterion": "immunomodulator use",
                        "requirement": {
                            "requirement_type": "use or exposure",
                            "expected_value": [
                                "lenalidomide",
                                "thalidomide"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                "criterions": [
                    {
                        "exact_snippets": "Histologic finding of prostate cancer",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "histologic finding",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system",
                        "criterion": "prostate cancer TNM stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "T1a",
                                "T1b"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                        "criterion": "history of completed treatment of stage 1-2 cancers",
                        "requirement": {
                            "requirement_type": "history of completed treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                        "criterion": "history of completed treatment of stage 1-2 cancers",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Exploratory cohort: RBC TD or nTD with momelotinib or pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
                "criterions": [
                    {
                        "exact_snippets": "RBC TD or nTD",
                        "criterion": "red blood cell transfusion dependence status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "transfusion dependent",
                                "non-transfusion dependent"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "with momelotinib or pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
                        "criterion": "treatment received",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "momelotinib",
                                "pacritinib"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                "criterions": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (≥3 months; female partner)",
                        "criterion": "hormonal contraceptive use (female partner)",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                        "criterion": "barrier contraceptive method (female partner)",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (\u00193 months; female partner)",
                        "criterion": "hormonal contraceptive use (female partner)",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                        "criterion": "barrier contraceptive method (female partner)",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "nTD cohort: Non-transfusion dependence, baseline Hgb <10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
                "criterions": [
                    {
                        "exact_snippets": "Non-transfusion dependence",
                        "criterion": "transfusion dependence",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "baseline Hgb <10 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "as defined on ≥3 assessments over 84 days prior to Screening",
                        "criterion": "hemoglobin assessments",
                        "requirement": {
                            "requirement_type": "number of assessments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "assessments"
                            }
                        }
                    },
                    {
                        "exact_snippets": "as defined on ≥3 assessments over 84 days prior to Screening",
                        "criterion": "hemoglobin assessments",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": "84 days prior to Screening"
                        }
                    },
                    {
                        "exact_snippets": "without RBC transfusion",
                        "criterion": "RBC transfusion",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Non-transfusion dependence",
                        "criterion": "transfusion dependence",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "baseline Hgb <10 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "as defined on \u00053 assessments over 84 days prior to Screening",
                                "criterion": "hemoglobin assessments",
                                "requirement": {
                                    "requirement_type": "number of assessments",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "assessments"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "as defined on \u00053 assessments over 84 days prior to Screening",
                                "criterion": "hemoglobin assessments",
                                "requirement": {
                                    "requirement_type": "time period",
                                    "expected_value": "84 days prior to Screening"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "without RBC transfusion",
                        "criterion": "RBC transfusion",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Granulocyte colony-stimulating factor (GCSF) OR granulocyte-macrophage CSF (GM-CSF)",
                "criterions": [
                    {
                        "exact_snippets": "Granulocyte colony-stimulating factor (GCSF) OR granulocyte-macrophage CSF (GM-CSF)",
                        "criterion": "colony-stimulating factor administration",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "GCSF",
                                "GM-CSF"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "15. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum FSH >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:",
                "criterions": [
                    {
                        "exact_snippets": "If female",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "postmenopausal",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "amenorrhea type",
                            "expected_value": [
                                "natural",
                                "spontaneous"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "serum FSH >40 mIU/mL at Screening",
                        "criterion": "serum FSH level",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy)",
                        "criterion": "time since surgical menopause",
                        "requirement": {
                            "requirement_type": "duration since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy)",
                        "criterion": "time since surgical menopause",
                        "requirement": {
                            "requirement_type": "surgical menopause type",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "hysterectomy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "contraception start time",
                            "expected_value": "on Day 1 or earlier"
                        }
                    },
                    {
                        "exact_snippets": "agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "contraception duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "11. Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count <50,000/µL at Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥25,000/µL and <1,000,000/µL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 25000,
                                        "unit": "/µL"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 1000000,
                                        "unit": "/µL"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "neutrophils ≥1,000/µL",
                        "criterion": "neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "/µL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total white blood cell (WBC) count <50,000/µL",
                        "criterion": "total white blood cell (WBC) count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "/µL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e25,000/\u00181L and <1,000,000/\u00181L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 25000,
                                        "unit": "/\u00181L"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 1000000,
                                        "unit": "/\u00181L"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "neutrophils \u001e1,000/\u00181L",
                        "criterion": "neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "/\u00181L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "total white blood cell (WBC) count <50,000/\u00181L",
                        "criterion": "total white blood cell (WBC) count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "/\u00181L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:",
                "criterions": [
                    {
                        "exact_snippets": "Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF.",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF.",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "primary MF",
                                "post ET MF",
                                "post PV MF"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                        "criterion": "symptomatic bleeding",
                        "requirement": {
                            "requirement_type": "relation to surgery",
                            "expected_value": "unrelated"
                        }
                    },
                    {
                        "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                        "criterion": "symptomatic bleeding",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "critical area or organ"
                        }
                    },
                    {
                        "exact_snippets": "bleeding causing a decrease in Hgb of ≥2 g/dL",
                        "criterion": "bleeding-induced hemoglobin decrease",
                        "requirement": {
                            "requirement_type": "hemoglobin decrease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bleeding ... leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                        "criterion": "bleeding-induced RBC transfusion",
                        "requirement": {
                            "requirement_type": "RBC transfusion units",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "units"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bleeding ... leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                        "criterion": "bleeding-induced RBC transfusion",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "6 months prior to Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                                "criterion": "symptomatic bleeding",
                                "requirement": {
                                    "requirement_type": "relation to surgery",
                                    "expected_value": "unrelated"
                                }
                            },
                            {
                                "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                                "criterion": "symptomatic bleeding",
                                "requirement": {
                                    "requirement_type": "location",
                                    "expected_value": "critical area or organ"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "bleeding causing a decrease in Hgb of \u00192 g/dL",
                        "criterion": "bleeding-induced hemoglobin decrease",
                        "requirement": {
                            "requirement_type": "hemoglobin decrease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "bleeding ... leading to transfusion of \u00192 units of RBCs in the 6 months prior to Screening",
                                "criterion": "bleeding-induced RBC transfusion",
                                "requirement": {
                                    "requirement_type": "RBC transfusion units",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "units"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "bleeding ... leading to transfusion of \u00192 units of RBCs in the 6 months prior to Screening",
                                "criterion": "bleeding-induced RBC transfusion",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "6 months prior to Screening"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
                "criterions": [
                    {
                        "exact_snippets": "Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
                        "criterion": "estimated glomerular filtration rate (eGFR)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
                        "criterion": "estimated glomerular filtration rate (eGFR)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Estimated glomerular filtration rate (eGFR) \u001930 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
                        "criterion": "estimated glomerular filtration rate (eGFR)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated glomerular filtration rate (eGFR) \u001930 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
                        "criterion": "estimated glomerular filtration rate (eGFR)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                "criterions": [
                    {
                        "exact_snippets": "Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)",
                        "criterion": "female partner surgical sterility",
                        "requirement": {
                            "requirement_type": "sterility_method",
                            "expected_value": [
                                "hysterectomy",
                                "bilateral oophorectomy",
                                "bilateral tubal ligation"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                        "criterion": "barrier method contraception",
                        "requirement": {
                            "requirement_type": "method_type",
                            "expected_value": [
                                "condom (male)",
                                "condom (female)",
                                "diaphragm"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                "criterions": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (≥3 months; female partner)",
                        "criterion": "hormonal contraceptive use (female partner)",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                        "criterion": "barrier contraceptive method (female partner)",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Stable hormonal contraceptive (\u00193 months; female partner)",
                        "criterion": "hormonal contraceptive use (female partner)",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                        "criterion": "barrier contraceptive method (female partner)",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Medical History, Participants with MF and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": "ongoing signs/symptoms related to the infection"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "response to treatment",
                            "expected_value": "without improvement despite appropriate treatment"
                        }
                    },
                    {
                        "exact_snippets": "Treatment History",
                        "criterion": "treatment history",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Medical History",
                        "criterion": "medical history",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with MF and Anemia",
                        "criterion": "diagnosis",
                        "requirement": {
                            "requirement_type": "disease",
                            "expected_value": "myelofibrosis (MF)"
                        }
                    },
                    {
                        "exact_snippets": "Participants with MF and Anemia",
                        "criterion": "diagnosis",
                        "requirement": {
                            "requirement_type": "comorbidity",
                            "expected_value": "anemia"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.",
                "criterions": [
                    {
                        "exact_snippets": "DIPSS score of ≥2 (intermediate 1 risk)",
                        "criterion": "DIPSS score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "DIPSS score of \u001e2 (intermediate 1 risk)",
                        "criterion": "DIPSS score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening",
                        "criterion": "peripheral blood myeloblasts",
                        "requirement": {
                            "requirement_type": "percentage of WBC differential",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Peripheral blood myeloblasts \u001910% of WBC differential at most recent evaluation prior to Screening",
                        "criterion": "peripheral blood myeloblasts",
                        "requirement": {
                            "requirement_type": "percentage of WBC differential",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Basal or squamous cell carcinoma",
                "criterions": [
                    {
                        "exact_snippets": "Basal or squamous cell carcinoma",
                        "criterion": "carcinoma type",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "basal cell carcinoma",
                                "squamous cell carcinoma"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Molecular International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate (ie, lower risk) MDS or MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.",
                "criterions": [
                    {
                        "exact_snippets": "Molecular International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate (ie, lower risk) MDS",
                        "criterion": "IPSS-R classification",
                        "requirement": {
                            "requirement_type": "category",
                            "expected_value": [
                                "very low",
                                "low",
                                "intermediate"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "MDS or MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T)",
                        "criterion": "disease diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "MDS",
                                "MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "as confirmed in the most recent local bone marrow biopsy report according to WHO criteria",
                        "criterion": "bone marrow biopsy confirmation",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "as confirmed in the most recent local bone marrow biopsy report according to WHO criteria",
                        "criterion": "bone marrow biopsy confirmation",
                        "requirement": {
                            "requirement_type": "criteria",
                            "expected_value": "WHO criteria"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD cohort and nTD cohort, JAK inhibitors allowed include ruxolitinib and fedratinib. For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review).",
                "criterions": [
                    {
                        "exact_snippets": "JAK inhibitors require 12 weeks of stable dosing prior to Screening",
                        "criterion": "JAK inhibitor dosing",
                        "requirement": {
                            "requirement_type": "stable dosing duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For the TD cohort and nTD cohort, JAK inhibitors allowed include ruxolitinib and fedratinib",
                        "criterion": "JAK inhibitor type (TD and nTD cohorts)",
                        "requirement": {
                            "requirement_type": "allowed agents",
                            "expected_value": [
                                "ruxolitinib",
                                "fedratinib"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
                        "criterion": "JAK inhibitor type (exploratory cohort)",
                        "requirement": {
                            "requirement_type": "allowed agents",
                            "expected_value": [
                                "momelotinib",
                                "pacritinib"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
                        "criterion": "JAK inhibitor type (exploratory cohort)",
                        "requirement": {
                            "requirement_type": "initial enrollment agent",
                            "expected_value": "momelotinib"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Peripheral blasts ≥5%",
                "criterions": [
                    {
                        "exact_snippets": "Peripheral blasts ≥5%",
                        "criterion": "peripheral blasts",
                        "requirement": {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Peripheral blasts \u001e5%",
                        "criterion": "peripheral blasts",
                        "requirement": {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. basal or squamous cell carcinoma",
                "criterions": [
                    {
                        "exact_snippets": "basal or squamous cell carcinoma",
                        "criterion": "carcinoma type",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "basal cell carcinoma",
                                "squamous cell carcinoma"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Serum ferritin ≥30 50 µg/L at Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Serum ferritin ≥30 50 µg/L at Screening",
                        "criterion": "serum ferritin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "µg/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum ferritin ≥30 50 µg/L at Screening",
                        "criterion": "serum ferritin",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum ferritin \u001930 50 \u00181g/L at Screening",
                        "criterion": "serum ferritin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "\u00181g/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum ferritin \u001930 50 \u00181g/L at Screening",
                        "criterion": "serum ferritin",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at Screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Platelet count ≥25,000/μL and <1,000,000/μL, and total WBC count <50,000/μL at Screening or otherwise approved by Sponsor",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥25,000/μL and <1,000,000/μL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 25000,
                                        "unit": "/μL"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 1000000,
                                        "unit": "/μL"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "total WBC count <50,000/μL",
                        "criterion": "total WBC count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "/μL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Platelet count ≥25,000/μL and <1,000,000/μL",
                                "criterion": "platelet count",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 25000,
                                                "unit": "/μL"
                                            },
                                            {
                                                "operator": "<",
                                                "value": 1000000,
                                                "unit": "/μL"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "total WBC count <50,000/μL",
                                "criterion": "total WBC count",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 50000,
                                        "unit": "/μL"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "otherwise approved by Sponsor",
                        "criterion": "otherwise approved by Sponsor",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.",
                "criterions": [
                    {
                        "exact_snippets": "Systemic corticosteroids are permitted for non-hematological conditions",
                        "criterion": "systemic corticosteroid use for non-hematological conditions",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if stable or decreasing dose for ≥28 days prior to Screening",
                        "criterion": "systemic corticosteroid dose stability",
                        "requirement": {
                            "requirement_type": "dose stability",
                            "expected_value": "stable or decreasing"
                        }
                    },
                    {
                        "exact_snippets": "if stable or decreasing dose for ≥28 days prior to Screening",
                        "criterion": "systemic corticosteroid dose stability",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening",
                        "criterion": "systemic corticosteroid dose",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone"
                            }
                        }
                    },
                    {
                        "exact_snippets": "receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening",
                        "criterion": "systemic corticosteroid dose",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 28,
                                "unit": "days immediately prior to Screening"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Systemic corticosteroids are permitted for non-hematological conditions",
                                "criterion": "systemic corticosteroid use for non-hematological conditions",
                                "requirement": {
                                    "requirement_type": "permitted",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "if stable or decreasing dose for \u001c28 days prior to Screening",
                                "criterion": "systemic corticosteroid dose stability",
                                "requirement": {
                                    "requirement_type": "dose stability",
                                    "expected_value": "stable or decreasing"
                                }
                            },
                            {
                                "exact_snippets": "if stable or decreasing dose for \u001c28 days prior to Screening",
                                "criterion": "systemic corticosteroid dose stability",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "receiving an equivalent to \u001c10 mg prednisone for the 28 days immediately prior to Screening",
                                "criterion": "systemic corticosteroid dose",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "mg prednisone"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "receiving an equivalent to \u001c10 mg prednisone for the 28 days immediately prior to Screening",
                                "criterion": "systemic corticosteroid dose",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 28,
                                        "unit": "days immediately prior to Screening"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.63",
                "criterions": [
                    {
                        "exact_snippets": "DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk)",
                        "criterion": "DIPSS score",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk)",
                        "criterion": "DIPSS score",
                        "requirement": {
                            "requirement_type": "risk group",
                            "expected_value": "intermediate 2"
                        }
                    },
                    {
                        "exact_snippets": "DIPSS score of ... ≥5 (high-risk)",
                        "criterion": "DIPSS score",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "DIPSS score of ... ≥5 (high-risk)",
                        "criterion": "DIPSS score",
                        "requirement": {
                            "requirement_type": "risk group",
                            "expected_value": "high-risk"
                        }
                    },
                    {
                        "exact_snippets": "primary MF, post PV MF, and/or post ET MF",
                        "criterion": "myelofibrosis type",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "primary MF",
                                "post PV MF",
                                "post ET MF"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "as confirmed in the most recent local bone marrow biopsy report",
                        "criterion": "bone marrow biopsy report",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "according to WHO 2016 criteria",
                        "criterion": "WHO 2016 criteria",
                        "requirement": {
                            "requirement_type": "diagnostic standard",
                            "expected_value": "WHO 2016"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                "criterions": [
                    {
                        "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                        "criterion": "symptomatic bleeding",
                        "requirement": {
                            "requirement_type": "relation to surgery",
                            "expected_value": "unrelated"
                        }
                    },
                    {
                        "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                        "criterion": "symptomatic bleeding",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "critical area or organ"
                        }
                    },
                    {
                        "exact_snippets": "bleeding causing a decrease in Hgb of ≥2 g/dL",
                        "criterion": "bleeding-induced hemoglobin decrease",
                        "requirement": {
                            "requirement_type": "hemoglobin decrease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bleeding ... leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                        "criterion": "bleeding-induced RBC transfusion",
                        "requirement": {
                            "requirement_type": "RBC transfusion units",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "units"
                            }
                        }
                    },
                    {
                        "exact_snippets": "bleeding ... leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                        "criterion": "bleeding-induced RBC transfusion",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "6 months prior to Screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                                "criterion": "symptomatic bleeding",
                                "requirement": {
                                    "requirement_type": "relation to surgery",
                                    "expected_value": "unrelated"
                                }
                            },
                            {
                                "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                                "criterion": "symptomatic bleeding",
                                "requirement": {
                                    "requirement_type": "location",
                                    "expected_value": "critical area or organ"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "bleeding causing a decrease in Hgb of \u00192 g/dL",
                        "criterion": "bleeding-induced hemoglobin decrease",
                        "requirement": {
                            "requirement_type": "hemoglobin decrease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "bleeding ... leading to transfusion of \u00192 units of RBCs in the 6 months prior to Screening",
                                "criterion": "bleeding-induced RBC transfusion",
                                "requirement": {
                                    "requirement_type": "RBC transfusion units",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "units"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "bleeding ... leading to transfusion of \u00192 units of RBCs in the 6 months prior to Screening",
                                "criterion": "bleeding-induced RBC transfusion",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "6 months prior to Screening"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Participants with MDS and Anemia",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "ongoing signs/symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                        "criterion": "infection status",
                        "requirement": {
                            "requirement_type": "improvement despite appropriate treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "14. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.",
                "criterions": [
                    {
                        "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": ">= 2x ULN"
                        }
                    },
                    {
                        "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "attribution",
                            "expected_value": [
                                "ineffective erythropoiesis",
                                "Gilbert's syndrome"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "investigator_approval",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "sponsor_approval",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                "criterions": [
                    {
                        "exact_snippets": "histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system)",
                        "criterion": "prostate cancer histology",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system)",
                        "criterion": "prostate cancer histology",
                        "requirement": {
                            "requirement_type": "TNM stage",
                            "expected_value": [
                                "T1a",
                                "T1b"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                        "criterion": "history of completed treatment of stage 1-2 cancers",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "completed"
                        }
                    },
                    {
                        "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                        "criterion": "history of completed treatment of stage 1-2 cancers",
                        "requirement": {
                            "requirement_type": "cancer stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "stage"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "stage"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                        "criterion": "history of completed treatment of stage 1-2 cancers",
                        "requirement": {
                            "requirement_type": "sponsor agreement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases",
                "criterions": [
                    {
                        "exact_snippets": "Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases",
                        "criterion": "secondary MDS",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": [
                                "chemical injury",
                                "treatment with chemotherapy",
                                "treatment with radiation from other diseases"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.",
                "criterions": [
                    {
                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening)",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening)",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "exception: dose stability or decrease for non-hematological conditions",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening)",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "exception: dose amount",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening)",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "exception: dose duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "the washout period must be completed prior to collection of Screening blood samples",
                        "criterion": "systemic corticosteroid washout period",
                        "requirement": {
                            "requirement_type": "completion before screening blood collection",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "not_criteria": {
                                "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for \u001e28 days prior to randomization for non-hematological conditions and receiving an equivalent to \u001e10 mg prednisone for the 28 days immediately prior to Screening)",
                                "criterion": "systemic corticosteroid use",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": false
                                }
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for \u001e28 days prior to randomization for non-hematological conditions and receiving an equivalent to \u001e10 mg prednisone for the 28 days immediately prior to Screening)",
                                        "criterion": "systemic corticosteroid use",
                                        "requirement": {
                                            "requirement_type": "exception: dose stability or decrease for non-hematological conditions",
                                            "expected_value": {
                                                "comparisons": [
                                                    {
                                                        "operator": ">=",
                                                        "value": 28,
                                                        "unit": "days"
                                                    }
                                                ]
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for \u001e28 days prior to randomization for non-hematological conditions and receiving an equivalent to \u001e10 mg prednisone for the 28 days immediately prior to Screening)",
                                        "criterion": "systemic corticosteroid use",
                                        "requirement": {
                                            "requirement_type": "exception: dose amount",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 10,
                                                "unit": "mg prednisone"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for \u001e28 days prior to randomization for non-hematological conditions and receiving an equivalent to \u001e10 mg prednisone for the 28 days immediately prior to Screening)",
                                        "criterion": "systemic corticosteroid use",
                                        "requirement": {
                                            "requirement_type": "exception: dose duration",
                                            "expected_value": {
                                                "operator": "=",
                                                "value": 28,
                                                "unit": "days"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "the washout period must be completed prior to collection of Screening blood samples",
                                "criterion": "systemic corticosteroid washout period",
                                "requirement": {
                                    "requirement_type": "completion before screening blood collection",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}